Olumiant (baricitinib) vs Rinvoq (upadacitinib)
Olumiant (baricitinib) vs Rinvoq (upadacitinib)
Olumiant (baricitinib) and Rinvoq (upadacitinib) are both oral medications classified as Janus kinase (JAK) inhibitors, used to treat conditions like rheumatoid arthritis by modulating the immune system. Olumiant is approved for the treatment of moderate to severe rheumatoid arthritis in adults who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies, and it has also been granted Emergency Use Authorization for COVID-19 in hospitalized adults. Rinvoq has a broader range of approvals for different inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and may be chosen based on the specific condition being treated, potential side effects, and the patient's overall health profile.
Difference between Olumiant and Rinvoq
| Metric | Olumiant (baricitinib) | Rinvoq (upadacitinib) |
|---|---|---|
| Generic name | Baricitinib | Upadacitinib |
| Indications | Rheumatoid arthritis, COVID-19 (under Emergency Use Authorization) | Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Atopic dermatitis |
| Mechanism of action | Janus kinase (JAK) inhibitor, inhibiting JAK1 and JAK2 | Selective Janus kinase (JAK) inhibitor, primarily inhibiting JAK1 |
| Brand names | Olumiant | Rinvoq |
| Administrative route | Oral | Oral |
| Side effects | Upper respiratory tract infections, nausea, headache, hypertension | Upper respiratory tract infections, nausea, increased liver enzymes, thrombosis |
| Contraindications | Active, serious infections; hypersensitivity to baricitinib | Active, serious infections; hypersensitivity to upadacitinib |
| Drug class | Janus kinase (JAK) inhibitor | Janus kinase (JAK) inhibitor |
| Manufacturer | Eli Lilly and Company | AbbVie Inc. |
Efficacy
Introduction to Olumiant (Baricitinib) in Rheumatoid Arthritis
Olumiant (baricitinib) is an oral medication approved for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. As a Janus kinase (JAK) inhibitor, baricitinib works by interfering with the JAK-STAT signaling pathway, which plays a crucial role in the inflammatory process of RA. Clinical trials have demonstrated that baricitinib can significantly reduce the signs and symptoms of RA, improve physical function, and inhibit the progression of structural joint damage.
Efficacy of Olumiant (Baricitinib) in Clinical Trials
The efficacy of Olumiant in the treatment of rheumatoid arthritis has been established through several pivotal phase III clinical trials, including the RA-BEAM and RA-BUILD studies. In these trials, patients treated with baricitinib showed a greater reduction in the number of tender and swollen joints compared to those receiving placebo or adalimumab, another medication commonly used for RA. Furthermore, baricitinib has been shown to achieve clinical remission in a subset of patients, indicating a significant suppression of disease activity.
Introduction to Rinvoq (Upadacitinib) in Rheumatoid Arthritis
Rinvoq (upadacitinib) is another oral JAK inhibitor specifically approved for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. Upadacitinib targets the JAK1 enzyme, which is believed to have a prominent role in the inflammatory process of RA. Clinical studies have shown that upadacitinib can lead to improvements in clinical symptoms, physical function, and quality of life for patients with RA.
Efficacy of Rinvoq (Upadacitinib) in Clinical Trials
The efficacy of Rinvoq in rheumatoid arthritis has been validated through multiple phase III trials, including the SELECT-NEXT and SELECT-COMPARE studies. In these trials, upadacitinib was found to be superior to placebo in reducing the signs and symptoms of RA, achieving clinical remission, and slowing the progression of joint damage. Patients treated with upadacitinib also experienced a rapid onset of action, with some patients reporting symptom improvement as early as two weeks after starting treatment.
Regulatory Agency Approvals
Olumiant
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Therapeutic Goods Administration (TGA), Australia
Rinvoq
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Access Olumiant or Rinvoq today
If Olumiant or Rinvoq are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us